InVivo Therapeutics Appoints Christopher McNulty as Vice President, Business Development

InVivo Therapeutics Appoints Christopher McNulty as Vice President, Business Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV), a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, today announced that Christopher McNulty has been appointed as Vice President, Business Development.

Most recently, Mr. McNulty served as Senior Director of Business Development at Repligen Corporation, where his responsibilities included out-licensing programs for rare neurodegenerative diseases. Previously, he was Director of Corporate Development at Seventh Sense Biosystems and Associate Director of Business Development and Alliance Management at Genzyme Corporation. While at Genzyme, he led business development activities in the area of neurology. Before joining Genzyme, Mr. McNulty held technical roles at Transform Pharmaceuticals and Cereon Genomics. He has an MBA from Harvard Business School, and BS and MEng degrees from MIT, where he performed research on biological hydrogels.

Michael Astrue, the interim CEO of InVivo, stated, "Going forward we expect our growth to be driven primarily by our success as a drug delivery company. In particular, our proprietary technology that can deliver proteins and other molecules locally on a time-release basis can provide significant value to most major pharmaceutical companies and biotech companies. Chris will be a key part of our transformation."

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. focuses on utilizing polymers as a platform technology to develop treatments for serious diseases and conditions, including improving function in individuals paralyzed as a result of traumatic spinal cord injury. The Company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011 the Company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit,

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties, and include statements regarding the Company's expectations with respect to the commencement of human clinical trials for the scaffold product and with respect to possible partnerships. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the identification of appropriate clinical sites; the Institutional Review Board process; the Company's ability to enter into partnerships; the Company's ability to obtain FDA approval to commercialize its products; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in our filings with the SEC, including our Form 10-K and 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.


InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Director, Investor Relations
[email protected]